Madrigal Pharmaceuticals, Inc. (MDGL) NASDAQ
535.01
+32.54(+6.48%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
535.01
+32.54(+6.48%)
Currency In USD
| Previous Close | 502.47 |
| Open | 529.89 |
| Day High | 558.32 |
| Day Low | 519.88 |
| 52-Week High | 615 |
| 52-Week Low | 265 |
| Volume | 195,650.76 |
| Average Volume | 345,405 |
| Market Cap | 12.27B |
| PE | -41.6 |
| EPS | -12.86 |
| Moving Average 50 Days | 485.43 |
| Moving Average 200 Days | 470.85 |
| Change | 32.54 |
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M. ET. The p
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
GlobeNewswire Inc.
Feb 11, 2026 10:00 AM GMT
Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra® (resmetirom) as the foundational treatmentMadrigal will develop next-generation siRN
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
GlobeNewswire Inc.
Feb 02, 2026 1:05 PM GMT
CONSHOHOCKEN, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2025 financial results on Thursday, Feb. 19, 2026, prior to the open of the U.S